Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus O Butler

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.
Elife|April 22, 2020
Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanomaKenji Murata, Munehide Nakatsugawa, Muhammed A Rahman, et al.
Developmental Cell|May 17, 2025
Neurodevelopmental hijacking of oligodendrocyte lineage programs drives glioblastoma infiltrationYiyan Wu, Benson Z Wu, Yosef Ellenbogen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.
JAMA Oncology|November 18, 2017
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical CarcinomaStephanie Lheureux, Marcus O Butler, Blaise Clarke, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumorsKirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Nature Immunology|July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapyGiselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
Cancer Research|November 11, 2025
Response to Immune Checkpoint Blockade is Enhanced in the Presence of Hematopoietic TET2 InactivationVincent Rondeau, Suraj Bansal, Marco M Buttigieg, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.
Elife|April 22, 2020
Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanomaKenji Murata, Munehide Nakatsugawa, Muhammed A Rahman, et al.
Developmental Cell|May 17, 2025
Neurodevelopmental hijacking of oligodendrocyte lineage programs drives glioblastoma infiltrationYiyan Wu, Benson Z Wu, Yosef Ellenbogen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.
JAMA Oncology|November 18, 2017
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical CarcinomaStephanie Lheureux, Marcus O Butler, Blaise Clarke, et al.
Journal for Immunotherapy of Cancer|August 6, 2020
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumorsKirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Nature Immunology|July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapyGiselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survivalMario Mandala, James Larkin, Paolo Antonio Ascierto, et al.
Cancer Research|November 11, 2025
Response to Immune Checkpoint Blockade is Enhanced in the Presence of Hematopoietic TET2 InactivationVincent Rondeau, Suraj Bansal, Marco M Buttigieg, et al.
Pageof 13